1. Market Research
  2. > Vaxin, Inc. - Product Pipeline Review - 2013

Vaxin, Inc. - Product Pipeline Review - 2013

  • July 2013
  • -
  • Global Markets Direct
  • -
  • 21 pages

Vaxin, Inc. - Product Pipeline Review - 2013

Summary

Global Markets Direct’s pharmaceuticals report, “Vaxin, Inc. - Product Pipeline Review - 2013” provides data on the Vaxin, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Vaxin, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Vaxin, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Vaxin, Inc. - Brief Vaxin, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Vaxin, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Vaxin, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Vaxin, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Vaxin, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Vaxin, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Vaxin, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Vaxin, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Vaxin, Inc. and identify potential opportunities in those areas.

Table Of Contents

Vaxin, Inc. - Product Pipeline Review - 2013
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Vaxin, Inc. Snapshot 4
Vaxin, Inc. Overview 4
Key Information 4
Key Facts 4
Vaxin, Inc. - Research and Development Overview 5
Key Therapeutic Areas 5
Vaxin, Inc. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Vaxin, Inc. - Pipeline Products Glance 9
Vaxin, Inc. Clinical Stage Pipeline Products 9
Phase I Products/Combination Treatment Modalities 9
Vaxin, Inc. - Early Stage Pipeline Products 10
Preclinical Products/Combination Treatment Modalities 10
Vaxin, Inc. - Drug Profiles 11
AdVAV Anthrax Vaccine 11
Product Description 11
Mechanism of Action 11
RandD Progress 11
Alzheimer's Vaccine 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
Epicutaneous Anthrax Vaccines 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
Influenza Vaccine 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
Tetanus Vaccine 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
Vaxin, Inc. - Pipeline Analysis 16
Vaxin, Inc. - Pipeline Products by Therapeutic Class 16
Vaxin, Inc. - Pipeline Products by Route of Administration 17
Vaxin, Inc. - Recent Pipeline Updates 18
Vaxin, Inc. - Locations And Subsidiaries 19
Head Office 19
Appendix 20
Methodology 20
Coverage 20
Secondary Research 20
Primary Research 20
Expert Panel Validation 20
Contact Us 21
Disclaimer 21

List of Tables

Vaxin, Inc., Key Information 4
Vaxin, Inc., Key Facts 4
Vaxin, Inc. - Pipeline by Indication, 2013 6
Vaxin, Inc. - Pipeline by Stage of Development, 2013 7
Vaxin, Inc. - Monotherapy Products in Pipeline, 2013 8
Vaxin, Inc. - Phase I, 2013 9
Vaxin, Inc. - Preclinical, 2013 10
Vaxin, Inc. - Pipeline By Therapeutic Class, 2013 16
Vaxin, Inc. - Pipeline By Route of Administration, 2013 17
Vaxin, Inc. - Recent Pipeline Updates, 2013 18

List of Figures

Vaxin, Inc. - Pipeline by Indication, 2013 6
Vaxin, Inc. - Pipeline by Stage of Development, 2013 7
Vaxin, Inc. - Monotherapy Products in Pipeline, 2013 8
Vaxin, Inc. - Pipeline By Therapeutic Class, 2013 16
Vaxin, Inc. - Pipeline By Route of Administration, 2013 17

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.